

1 **Supplementary materials**

2 Table S1. Strains and plasmids used in this study

3

| Name | Description | Reference |
|--|---|------------------------------------|
| <i>Escherichia coli</i> | | |
| DH5α | F- φ80 <i>lacZ</i> ΔM15 Δ(<i>lacZYA-argF</i>)U169 <i>recA1 endA1 hsdR17</i> (r ⁻ , m ⁺) <i>phoA supE44 thi-1</i> <i>gyrA96 relA1 λ- tonA</i> | New England Biolabs (NEB) |
| BL21 | <i>fhuA2 [lon] ompT gal [dcm] ΔhsdS</i> | NEB |
| HB101 | | NEB |
| HB101 pRK24 | HB101 transformed with pRK24 | (1) |
| RT1255 | pMMBneo:: <i>R20291_rsh</i> -His6 in DH5α | (2) |
| RT1270 | pMMBneo:: <i>R20291_rsh</i> -His6 in BL21 | (2) |
| <i>Clostridioides difficile</i> | | |
| 630 | Wild type | |
| 630Δ <i>erm</i> | Wild type 630 lacking erythromycin resistance gene <i>ermB</i> | (3) |
| R20291 | Wild type | |
| CEP18 | pRF185:: <i>phiLOV2.12.1</i> in R20291 | This study |
| CEP19 | pRF185:: <i>phiLOV2.12.1</i> in 630Δ <i>erm</i> | This study |
| CEP21 | PrelQ630Δ <i>erm</i> :: <i>phiLOV2.12.1</i> in R20291 | This study |
| CEP22 | Prsh630Δ <i>erm</i> :: <i>phiLOV2.12.1</i> in 630Δ <i>erm</i> | This study |
| CEP23 | PrelQ630Δ <i>erm</i> :: <i>phiLOV2.12.1</i> in 630Δ <i>erm</i> | This study |
| CEP25 | PrshR20291:: <i>phiLOV2.12.1</i> in R20291 | This study |
| <i>Plasmids</i> | | |
| pMMBneo | Low copy expression vector, <i>Ptac</i> , <i>neo</i> cassette, <i>KanR</i> | (2) |
| pRF185 | <i>tetR</i> | (4) |

| | | |
|---|---|------------|
| pMMBneo::R20291_ <i>rsh</i> -His6 | R20291 <i>rsh</i> ligated into KpnI/PstI sites of pMMBneo | (2) |
| pMMBneo::R20291_ <i>rshREL</i> -His6 | <i>rel</i> amplified from R20291 <i>rsh</i> and ligated into KpnI/PstI sites of pMMBneo | This study |
| pRF185::phiLOV2.12.1 | <i>phiLOV2.1</i> downstream of tetracycline-inducible promoter ligated into BamHI/KpnI sites of pRF185 | (4) |
| PrelQ630 Δ <i>erm</i> ::phiLOV2.12.1 | Predicted promoter upstream of 630 Δ <i>erm relQ</i> amplified and ligated into BamHI/KpnI sites of pRF185::phiLOV2.12.1 | This study |
| Prsh630 Δ <i>erm</i> ::phiLOV2.12.1 | Predicted promoter upstream of 630 Δ <i>erm rsh</i> amplified and ligated into BamHI/KpnI sites of pRF185::phiLOV2.12.1 | This study |
| PrshR20291::phiLOV2.12.1 | Predicted promoter upstream of R20291 <i>rsh</i> amplified and ligated into BamHI/KpnI sites of pRF185::phiLOV2.12.1 | This study |
| pMSPT | Low copy expression vector | (5) |
| pMSPT:: <i>as_rsh</i> | Antisense RNA to the mRNA of <i>rshCd</i> ligated into the SphI/XhoI sites of pMSPT | This study |

4
5

6 Table S2. Sequences of oligonucleotide primers used in this study

| Name | Sequence (5' to 3') | Reference |
|------------------------|---|------------|
| Cloning primers | | |
| rsh_F KpnI | CAGGTACCGGTTATATGCATGATAAAG AATTACAAG | (2) |
| rsh_R PstI | CCCTGCAGCTAATGGTGATGGTGATGGTGAT TTGTCATTCTATAAATAC | (2) |
| pRF185_F | CTGGACTTCATGAAAACTAAAAAATATTG | This study |
| pRF185_R | CACCGACGAGCAAGGCAAGACCG | This study |
| phiLOV2.1_F | GCTAGCCCAGGTATGATTGAAAAAGTTTTG TTATTACTG | This study |
| phiLOV2.1_R | CATGGATCCTTATTAACATGATCTG | This study |
| Prsh_F BamHI | TATAGGATCCGGAAAGTTACCAGGTGAAGTT GA | This study |
| Prsh_R KpnI | ATATGGTACCCACCTATTTTGTATAAAATTT TAATATATATG | This study |
| PrelQ_F BamHI | TATAGGATCCATGGCAAGCAAGTTATATCG | This study |
| PrelQ_R KpnI | ATATGGTACCCCTTTATTTGTTTTTATGACCT TC | This study |
| relQ_F | CAAGAATTCCACTATGGAGCTTGTAATCA | This study |
| relQ_R | CAAGGATCCCATATTGCTCACCCCTTATTTG | This study |
| pMSPT_F | CTAAAGGGCAAAGTGAGTATGG | This study |
| pMSPT_R | GACGAGCAAGGCAAGACC | This study |
| rsh_as_F | GGTATGCATGCTGCATAAAC | This study |
| rsh_as_R | CCTAGCTCTCGAGACCAAC | This study |
| rshREL_F KpnI | CAGGTACCATGAAAGAAGAACTCAATCTG | This study |
| rshREL_R PstI | CCCTGCAGCTAATGGTGATGGTGATGGTGA CTATTAATACATCTTCTTTAAGTGC | This study |
| qRT-PCR primers | | |
| rpoCq_F | CTAGCTGCTCCTATGTCTCACATC | (1) |
| rpoCq_R | CCAGTCTCTCCTGGATCAACTA | (1) |

| | | |
|---------|--------------------------|------------|
| rsh_qF | AAAATAGGTGGTTAT | This study |
| rsh_qR | TCAATTTTATTATCCCTCCTTTGA | This study |
| relQ_qF | CATTGCGGGTTCAAAGGAAAT | This study |
| relQ_qR | CATTGCGGGTTCAAAGGAAAT | This study |


7

8 Underlined: restriction sites


9 Bold: sequence encoding hexa-histidine tag

10

11
12
13
14
15
16
17
18
19
20



21 **Figure S1. HPLC chromatogram of nucleotides.** GTP, GDP, and GMP
22 standards run separately at 20 μ M concentration. Peaks resolved at 252 nm
23 demonstrate that RSHCd's inability to utilize GTP for a substrate is not an artifact
24 of substrate breakdown and/or contamination.



25

26 **Figure S2. ITC thermogram and Wiseman plots of RSHCd interactions with**

27 **GXP at 37°C.** Binding of RSHCd to GDP (left) and GTP (right). The upper panels

28 show raw data for titration of GXP with RSHCd, and the lower panels show the

29 integrated heats of binding obtained from the raw data. The data were fitted to a

30 single-binding site model. Each value is the average of three repeat experiments

31 and the standard deviation \pm are shown.

32

33

34

35

36


37

38

39

40

41



42

43

44

45

46

47

48

| Sublethal concentration | Clindamycin (µg/mL) | Metronidazole (µg/mL) |
|-------------------------|---------------------|-----------------------|
| 0.25X | 4.00 | 0.075 |
| 0.5X | 8.00 | 0.15 |
| 1X | 16.0 | 0.30 |

49

Figure S3. Sublethal concentrations for clindamycin and metronidazole

50

against R20291. Sublethal concentrations of antibiotics for wild-type *C. difficile*

51

strain R20291 were analyzed using the standard minimum inhibitory

52

concentrations (MICs) determination method. ON starter culture of R20291 was

53

inoculated (1:10) into fresh BHIS media treated with increasing concentrations of

54

either clindamycin or metronidazole. Cells were incubated anaerobically at 37°C

55

for 12 h to monitor growth inhibition. The sublethal concentrations are shown for

56

four biological replicates.

57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83




Figure S4. Sequence alignments of the upstream promoter regions used in the
(A) *Prsh* and (B) *PreIQ* transcriptional reporters.

84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117




Figure S5: Minimum inhibitory concentration for ATc against *C. difficile* RNAi strains. MIC for *C. difficile* R20291 RNAi strain harboring the respective plasmids were analyzed in BHIS plus thiamphenicol (15 µg/mL) media with increasing concentrations of ATc. ON starter cultures of RNAi strains were inoculated into media (1:20) and incubated anaerobically at 37°C for 24 h to monitor growth inhibition. The MIC against empty vector (pMSPT) and asRNA vector (*as_rsh*) expressing strains are shown for two biological replicates. 0.5 µg/mL was determined to be the sublethal concentration of ATc against both RNAi strains to be used for end point growth assays.

118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156




Figure S6: TLC autoradiogram of *in vitro* RSHCd transferase activity at different GDP:GTP ratio. *In vitro* transferase reaction using equimolar concentration of GDP and GTP (0.15 mM each) and 2X more GTP (0.2 mM) than GDP (0.1mM) keeping the total [substrate] equivalent to 0.3 mM. Failure to detect pppGpp suggests that RSHCd is incapable of utilizing GTP at equimolar concentration of GDP and at excess concentration of GTP than GDP.

157 **Works cited:**

158

- 159 1. Purcell, E. B., McKee, R. W., McBride, S. M., Waters, C. M., and Tamayo, R.
160 (2012) Cyclic diguanylate inversely regulates motility and aggregation in
161 *Clostridium difficile*. *Journal of bacteriology* **194**, 3307-3316
- 162 2. Pokhrel, A., Poudel, A., and Purcell, E. B. (2018) A Purification and In Vitro
163 Activity Assay for a (p) ppGpp Synthetase from *Clostridium difficile*. *JoVE*
164 (*Journal of Visualized Experiments*), e58547
- 165 3. Hussain, H. A., Roberts, A. P., and Mullany, P. (2005) Generation of an
166 erythromycin-sensitive derivative of *Clostridium difficile* strain 630
167 (630Deltaerm) and demonstration that the conjugative transposon Tn916DeltaE
168 enters the genome of this strain at multiple sites. *J Med Microbiol* **54**, 137-141
- 169 4. Buckley, A. M., Jukes, C., Candlish, D., Irvine, J. J., Spencer, J., Fagan, R. P.,
170 Roe, A. J., Christie, J. M., Fairweather, N. F., and Douce, G. R. (2016) Lighting
171 Up *Clostridium Difficile*: Reporting Gene Expression Using Fluorescent Lov
172 Domains. *Scientific Reports* **6**, 23463
- 173 5. Marreddy, R. K., Wu, X., Sapkota, M., Prior, A. M., Jones, J. A., Sun, D.,
174 Hevener, K. E., and Hurdle, J. G. (2018) The fatty acid synthesis protein enoyl-
175 ACP reductase II (FabK) is a target for narrow-spectrum antibacterials for
176 *Clostridium difficile* infection. *ACS infectious diseases* **5**, 208-217
- 177